Andrew Moreno

DocwireNews

The phase III COMMANDS trial evaluated luspatercept in adults with lower-risk myelodysplastic syndromes (MDS) and red blood cell (RBC) transfusion dependence. A subsequent analysis has measured the long-term transfusion independence benefit of this agent compared with epoetin alfa. The analysis was presented at the 66th American Society of Hematology Annual Meeting &amp; Exposition in San Diego, California.
According to lead author of the analysis Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, “luspatercept continued to demonstrate sustained and durable clinical benefit versus epoetin alfa, maintaining responses of [1.5 years or longer] across multiple clinically relevant subgroups including ring sideroblast negative status, low baseline serum erythropoietin, and non-mutated SF3B1.”
Patients enrolled in the trial had very low-, low-, or intermediate-risk MDS and were erythroid-stimulating agent naive. Following randomization, 182 patients received subcutaneous luspatercept dosed at 1.0 mg/kg once every three weeks, and 181 received subcutaneous epoetin alfa dosed at 450 IU/kg once weekly. The two cohorts had comparable baseline characteristics.
By data cutoff, a longest RBC transfusion independence period of a year or longer had been achieved by 44.5% of patients in the luspatercept cohort and 27.6% of those in the epoetin alfa cohort (P=.0003), with a common risk difference of 16.7 and odds ratio (OR) of 2.2.
A longest transfusion independence period of 1.5 years or longer was achieved by 30.2% of the luspatercept cohort and 13.8% of the epoetin alfa cohort (P&lt;.0001), with a common risk difference of 16.3 and OR of 2.8. Examination by patient subgroup, again, showed a trend where more patients in the luspatercept cohort than in the epoetin alfa cohort achieved transfusion independence of 1.5 years or longer.
Transfusion independence lasting 12 weeks or longer was achieved by 76.4% of the luspatercept cohort and 55.8% of the epoetin alfa cohort, and of these percentages, a cumulative transfusion independence lasting a year or longer was achieved by 64.7% and 54.5%, respectively.
“Progression rates to high-risk MDS and acute myeloid leukemia were low in both treatment arms,” Dr. Garcia-Manero mentioned regarding the analysis findings.
Reference
Garcia-Manero G, Santini V, Zeidan AM, et al. Long-term response analysis of transfusion independence in erythropoiesis stimulating agent–naive patients with very low-, low-, or intermediate-risk myelodysplastic syndromes treated with luspatercept vs epoetin alfa in the COMMANDS trial. Abstract #350. Presented at the 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.

Rob Dillard

Assessing Axillary Pathologic Complete Response in Triple-Negative Breast Cancer

SABCS 2024

Jordana Jampel

Transthyretin Tetramer Destabilization Associated With All-Cause Mortality in Danish Population Study

Preventive Cardiology

Accelerated Disease Progression in Head, Neck Cancers Correlates With Cortisol Rhythm Disruption

Head and Neck Cancer

Latest News

COMMANDS Trial: Luspatercept Long-Term Transfusion Benefit Compared With Epoetin Alfa

ASH 2024

Across several patient subgroups luspatercept was observed to produce longer durations of transfusion independence.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe